Pfizer and Takeda join BIO Ventures to tackle Africa cancer crisis
Pfizer and Takeda have joined together with non-profit BIO Ventures for Global Health (BVGH) and the African Organisation for Research and Training in Cancer to launch the African Access Initiative (AAI).
Launched yesterday, June 21, at the 2017 BIO International Convention, the initiative will work to tackle Africa’s emerging cancer crisis by expanding access to oncology medicines and improving cancer care in Africa.
According to a statement from the initiative, cancer kills 60% more people in Africa than malaria, and the number of cancer deaths is expected to increase by almost 70% by 2030.
Four African countries—Cameroon, the Ivory Coast, Kenya and Nigeria—have been selected for the first phase of the initiative.
Freda Lewis-Hall, executive vice president and chief medical officer of Pfizer, said: “At Pfizer, we strive to provide access to safe, effective, and affordable medicines worldwide, and the need is particularly urgent in oncology given the rising burden of cancer.”
Lewis-Hall added that Pfizer realises that “no single entity can accomplish this ambitious goal, so we are excited to partner with BVGH, African governmental and healthcare leaders, and leading cancer researchers on AAI”.
Christophe Weber, president and CEO of Takeda, added: “In line with Takeda’s values, our access to medicines strategy will expand on our existing commitments to enhance global health, so that our innovative and potentially life-saving medicines can be more accessible and affordable to patients in regions such as Sub-Saharan Africa.”
The 2017 BIO International Convention is taking place in San Diego from June 19 to 22.
Today’s stories:
Section 101 raises fundamental question: 3M
Panellists tackle patent concerns after Brexit
FBI agent and lawyers provide trade secret tips
Industry at a crossroads over section 101
Academic patents gave $1.3tn to US output
David Cameron talks Brexit, Trump and genomes
Hospira sued for infringing allergic injection patent
Google’s parent company invests $300m in biotech
Did you enjoy reading this story? Sign up to our free newsletters and get stories like this sent straight to your inbox.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk